

CanBas Completes 2nd closing of its 4th financing



Numazu-city, Shizuoka, Japan - February 16, 2006 -- CanBas Co., Ltd., a privately held drug discovery company located in Numazu-city, Shizuoka, Japan, announced today that the company has completed the 2nd closing of its 4th financing.

This round, which closed November 30, 2005 and February 8, 2006, was co-led by NIF SMBC Ventures and MVC (Mitsui Ventures). 24 other VC firms and 10 strategic investors participated in this round.

This financing round amounted to JPY 2.5 billion (approximately \$21.2 million) in total.

About CanBas

CanBas was spun off of the research of three scientists from the Nagoya City Medical School and Fujita Health Medical School. These scientists founded CanBas as a drug development biotech with help by Angels and Venture Capitalists in 2000.

CanBas's core technologies include drugs that target the G2 checkpoint and a screening system to find selective blockers of the G2 checkpoint.

The company's leading compound CBP501 is currently under investigation in Phase I clinical trial in the United States.

For more information about CanBas, please visit www.canbas.co.jp.

Company Contact

Masashi Suganuma, M.D., Ph.D.

Executive Vice President & COO

Phone: +81-55-954-3666

Fax: +81-55-954-3668

or >> [Contact form](#)